Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Updates on the SECOMBIT trial

Paolo A. Ascierto, MD, National Tumor Institute, Milan, Italy, updates us on the results from the prospective randomized Phase II SECOMBIT clinical trial (NCT02631447), which evaluates the best sequencing strategy in patients with metastatic melanoma and BRAF V600 mutation. In this study, the combination of ipilimumab and nivolumab followed by the combination of encorafenib and binimetinib, with the opposite sequence (combination targeted therapy followed by combination immunotherapy), or with a treatment regimen consisting of 8 weeks combination targeted therapy, followed by combination immunotherapy, and combination targeted therapy again (sandwich) was evaluated in BRAF V600 mutated metastatic melanoma. Dr Ascierto reports an interesting trend in favour of combination therapy as the first treatment, with a 2- and 3-year overall survival (OS) of 73% and 62% respectively, in comparison to 65% and 54% for patients treated with combination targeted therapy first, and 69% and 60% for patients in the sandwich arm. Similarly, the response rate for patients first treated with combination immunotherapy was 45%, in comparison to 25% for patients first treated with combination targeted therapy. Dr Ascierto underlines that a longer follow-up is required to see if this trend persists in the long-term. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.